Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

SBMT announces 2012 recipients of Pioneers in Medicine, Technology and Healthcare Policy Awards

Today, the Society for Brain Mapping & Therapeutics announced the 2012 recipients of the organization's prestigious Pioneers in Medicine, Technology, and Healthcare Policy Awards.

17 Mar 2012

$Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy$

Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy

Medtronic, Inc. today announced that a patient from Kempenhaeghe-Heeze (The Netherlands) is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact and safety of deep brain stimulation (DBS) in patients with refractory epilepsy.

From Medtronic 17 Mar 2012

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that the first patient was dosed in a phase 2 clinical trial in the US for patients suffering with chronic constipation using their new chemical entity YKP10811.

17 Mar 2012

$Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy$

Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy

Medtronic, Inc. today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation (DBS) Therapy for refractory epilepsy patients.

From Medtronic 16 Mar 2012

Third International Symposium on Thymosins in Health and Disease to take place on GW campus

The George Washington University is host to the world's leaders in the area of research that focuses on Thymosins- small proteins present in many animal tissues that have diverse biological activities- Two in particular, thymosins α1 and β4, have potentially important uses in medicine, and research has already progressed from the laboratory to the clinic.

16 Mar 2012

Longer looks: Last interview with Oregon's assisted-suicide law architect; Med students spurn primary care for hospital jobs

Dr. Peter Goodwin, a family physician and right-to-die activist, took his own life on March 11, 2012, at age 83. He did it legally, with the blessing of his family and doctors, under the Oregon law allowing physician-assisted suicide -; the first such law in the country -; that Goodwin was instrumental in creating. … He did not look like a dying man; he was chirpy and alert ... However, as a result of his fatal disease -; a Parkinsons-like condition called coritcobasal degeneration -; he could not use his right hand or do much reliably with his left.

16 Mar 2012

Many people do not recognize stroke symptoms

Nationwide ambulance use by patients suffering from a stroke has not changed since the mid-1990s, even though effective stroke treatments are now available.

15 Mar 2012

Women with retinopathy more likely to have cognitive problems

People with mild vascular disease that causes damage to the retina in the eye are more likely to have problems with thinking and memory skills because they may also have vascular disease in the brain, according to a study published in the March 14, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

15 Mar 2012

People with RBD more likely to develop Parkinson's, MCI

People with symptoms suggesting rapid eye movement sleep behavior disorder, or RBD, have twice the risk of developing mild cognitive impairment (MCI) or Parkinson's disease within four years of diagnosis with the sleep problem, compared with people without the disorder, a Mayo Clinic study has found.

15 Mar 2012

New national effort to accelerate development of therapies for neurological diseases

The National Institute for Neurological Disorders and Stroke (NINDS) has selected Columbia University College of Physicians and Surgeons and Weill Cornell Medical College to participate in a new national effort to accelerate the development of therapies for people with neurological diseases.

14 Mar 2012

CME conference on deep brain stimulation for movement disorders

CME Conference for physicians and health care professionals on deep brain stimulation for movement disorders, obsessive-compulsive disorder and depression

14 Mar 2012

Potential new way to treat rare inherited metabolic disorders

A University of Michigan cell biologist and his colleagues have identified a potential drug that speeds up trash removal from the cell's recycling center, the lysosome.

14 Mar 2012

FDA approves Botox injections for overactive bladder

When you think of Botox injections, you probably think of getting rid of unwanted wrinkles around the eyes or forehead, but recently the US Food and Drug Administration (FDA) approved using the injections to help patients with neurological conditions who suffer from incontinence, or an overactive bladder.

14 Mar 2012

JAK-STAT inhibitors reverse MS-like disease in mice

A new class of drugs completing clinical trials soon for rheumatoid arthritis should be examined as a treatment for multiple sclerosis, according to the authors of a University of Alabama at Birmingham study published today in the Proceedings of the National Academy of Sciences.

13 Mar 2012

Human diseases with Drosophila counterparts discussed at annual conference

More than two-thirds of human genes have counterparts in the well-studied fruit fly, Drosophila melanogaster, so although it may seem that humans don't have much in common with flies, the correspondence of our genetic instructions is astonishing. In fact, there are hundreds of inherited diseases in humans that have Drosophila counterparts.

12 Mar 2012

OPKO Health, Scripps Research partner to commercialize Parkinson's disease compound, SR 3306

The Scripps Research Institute and OPKO Health, Inc. today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

Allon advances into second phase of work in preclinical PD model

Allon Therapeutics Inc. announced today the completion of its first phase of work in a preclinical Parkinson's disease model and advancement into the second phase of work. Both phases are funded by The Michael J. Fox Foundation for Parkinson's Research and carried out by Prof. Marie-Francoise Chesselet's lab at the University of California Los Angeles.

12 Mar 2012

DeSyRe develops new design techniques for future Systems-on-Chips

For pacemakers and other implantable medical devices there are three key factors: extreme reliability, small size, and long longevity. In the EU project DeSyRe, researchers tackle these issues with a new approach: building a reliable system on unreliable components. Ioannis Sourdis, project leader, today explains the DeSyRe's approach in a tutorial on "Hardware and software design and verification for safety critical electronic systems" during the DATE 2012 conference in Dresden.

12 Mar 2012

TSRI, OPKO Health to develop and commercialize SR 3306 for Parkinson's

OPKO Health, Inc. and The Scripps Research Institute today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

Gene that causes aggression in men under stress discovered

Scientists have found that “macho” gene that makes men behave more aggressively than women under stress. They say this one gene could explain why men have a 'fight or flight' response while women are more likely to try and defuse the situation. The study has been published in the journal BioEssays.

11 Mar 2012